On June 20, 2024, Prairie Capital partnered with founder Dr. Zahra Kashi and senior management to recapitalize Kashi Clinical Laboratories (“Kashi” or the “Company”). Headquartered in Portland, OR, Kashi Clinical Laboratories is a fully accredited clinical laboratory providing specialized solutions to academic institutions, biopharma, hospitals, long-term care facilities and transplant centers around the world.
The Company was founded in 2006 to provide high-resolution HLA typing for transplant donor matching. Over time, Kashi expanded its service offering to include post-transplant monitoring, genomic sequencing and other diagnostic testing. Kashi enjoys industry-leading customer satisfaction and is renowned for its rapid turnaround time, scientific expertise, customer service and innovation using state-of-the-art technology.
Kashi’s aggregate market opportunity exceeds $20 billion, and demand for Kashi’s lab offerings is robust. Transplant volume is growing due to an aging population, increased prevalence of cancer / acute diseases, dietary habits and other factors. Kashi’s full suite of lab services provide customers with critical pre-transplant matching and precise post-transplant monitoring. In addition, biotech and pharmaceutical organizations spend more than $250 billion per year researching and developing therapeutics, the services for which are routinely outsourced to independent labs. Kashi’s ability to provide accurate and timely HLA-typing in addition to a variety of complementary tests provides a unique service offering to numerous organizations.
Prairie partnered with the founder and senior management to accelerate the growth of Kashi through company-building investments in human capital, sales & marketing, technology, infrastructure, new services and add-on acquisitions.
For more information on Kashi Clinical Laboratories and/or any add-on acquisition opportunities, please contact:
Michael Praljak at mpraljak@prairie-capital.com
Sean McNally at smcnally@prairie-capital.com